Mersana Therapeutics Announces Initiation of the UPGRADE Phase 1 Platinum Combination Cohort for UpRi in Platinum-Sensitive Ovarian Cancer
UPGRADE umbrella study designed to evaluate UpRi in combination with other therapies, starting with carboplatin
CAMBRIDGE, Mass., July 28, 2021 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused…
